This page shows the details of why an item matched the keywords from your search.
| Item Type | Name |
|
Concept
|
Transplantation, Autologous
|
|
Academic Article
|
Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204).
|
|
Academic Article
|
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.
|
|
Academic Article
|
Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myeloma.
|
|
Academic Article
|
Evolving strategies in the initial treatment of multiple myeloma.
|
|
Academic Article
|
Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults.
|
|
Academic Article
|
Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study.
|
|
Academic Article
|
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
|
|
Academic Article
|
Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis.
|
|
Academic Article
|
Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients.
|
|
Academic Article
|
Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.
|
|
Academic Article
|
Knowing the unknowns in high risk multiple myeloma.
|
|
Academic Article
|
Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma.
|
|
Academic Article
|
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.
|
|
Academic Article
|
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.
|
- Transplantation Autologous